Form D · Biotechnology
Tractus Corp
Austin, TX · CIK 0002003155
Offering snapshot reported Dec 13, 2023 · SEC filing
- Reported sold
- $865K Offering amount: $1M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $8K Reported outside-investor minimum
- First sale
- Dec 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 13, 2023 | Initial | $865,000 | No comparison | 15 | SEC filing |
| Dec 13, 2023 | Initial | $177,500 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-499456
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Dec 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Campbell Iii | Director |
| Leonard Davenport | Director |
| Brad Hummel | Director, Executive |
| August Peterson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1710 #1 Rockmoor Avenue
Austin, TX, 78703
Austin, TX, 78703